62-Year-Old with Advanced Colorectal Cancer: WIN Molecular Tumor Board Review | Oncotarget скачать в хорошем качестве

62-Year-Old with Advanced Colorectal Cancer: WIN Molecular Tumor Board Review | Oncotarget

Oncotarget #published this #trending precision #oncology paper on June 17, 2025 in Volume 16, entitled “Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment" by #researchers from Vall d’Hebron University Hospital, Barcelona, Spain; Vall d’Hebron Institute of Oncology, Barcelona, Spain; Worldwide Innovative Network (WIN) Association - WIN Consortium, Chevilly-Larue 94550, France; Medical College of Wisconsin, Milwaukee, WI; IFOM ETS – The AIRC Institute of Molecular Oncology, Milan, Italy; Legorreta Cancer Center at Brown University, Providence, RI. #cancer #colorectalcancer #chemotherapy #casereport #research #openaccess #openscience #peerreview #journal #publication #publishing #meded DOI - https://doi.org/10.18632/oncotarget.28744 Correspondence to - Shai Magidi - [email protected] Worldwide Innovative Network (WIN) Association - https://winconsortium.org/ Abstract Heavily pretreated metastatic colorectal cancer (mCRC) poses significant therapeutic challenges. Advances in molecular profiling enables personalized strategies. We present a 62-year-old male with mCRC harboring BRAF, MET, APC, TP53 and NRAS alterations, following FOLFOX and FOLFIRI, dabrafenib plus panitumumab, and a BRAF inhibitor clinical trial, each leading to initial responses followed by disease progression. WIN Consortium International Molecular Tumor Board (MTB), included experts from institutions across 13 countries. Enrollment in suitable clinical trials was explored but limited by availability. Personalized combinations suggested included amivantamab-vmjw (anti-MET/EGFR antibody) (one-third standard dose) (for MET amplification and due to prior response to anti-EGFR antibody), trametinib, 1 mg po daily (MEK inhibitor for BRAF V600E mutation), and regorafenib (may have WNT inhibitor activity relevant to APC mutation; VEGFR activity relevant since TP53 alterations upregulate VEGF/VEGFR axis) starting at 40 mg po daily three weeks on, one week off. Another option was trametinib at 1 mg daily, cetuximab (EGFR antibody), 250 mg/m² IV every two-weeks, and cabozantinib (MET and VEGFR inhibitor), 40 mg po daily. FOLFOXFIRI combined with bevacizumab, or liver-directed therapies for hepatic metastases, or regorafenib with 5FU, or crizotinib (MET inhibitor) combined with regorafenib or dabrafenib, was also suggested. This case emphasizes the critical role of comprehensive molecular profiling and personalized therapeutic approaches in managing complex mCRC. The WIN International MTB aims to provide treatment and biomarker analysis discussion with the ultimate goal of optimizing treatment efficacy by targeting specific molecular alterations, though final treatment decisions remain at the discretion of the treating physician. Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/e... Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, precision oncology, molecular tumor board, colorectal carcinoma, cancer management About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube -    / @oncotargetjournal   LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJz... Media Contact [email protected] 18009220957